11月20日，中国生物制药(01177)盘中上涨5.2%，截至13:13，报3.44元/股，成交1.48亿元。
中国生物制药有限公司及附属公司是中国领先的创新研究和研发驱动型医药集团，业务覆盖医药研发平台、智能化生产和强大销售体系全产业链，其产品在肿瘤、肝病、呼吸系统、外科/镇痛四大治疗领域处于优势地位。2018年，该公司连续六年入选美国权威杂志《制药经理人》发布的“全球制药企业TOP50”，连续三年获评《福布斯》(亚洲)“亚太最佳公司50强”，且在北京、上海、南京、连云港、青岛等地拥有多个药品生产基地，核心企业正大天晴药业集团、北京泰德制药股份有限公司均多年位列中国医药工业企业百强榜。
截至2024年中报，中国生物制药营业总收入158.74亿元、净利润30.17亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.